Inflammation and schizophrenia

Expert Review of Neurotherapeutics

Volumn 7, Issue 7, 2007, Pages 789-796

  Fan, Xiaoduo ^a,b,c   Goff, Donald C ^a,b   Henderson, David C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Freedom Trail Clinic   (United States)

Author keywords

Cytokine; Inflammation; Insulin resistance; Metabolic syndrome; Schizophrenia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CELECOXIB; CLOZAPINE; CYTOKINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIOGLITAZONE; RISPERIDONE; ROSIGLITAZONE;

ALZHEIMER DISEASE; APOPTOSIS; ATHEROSCLEROSIS; BRAIN BLOOD VESSEL; BRAIN HYPOXIA; BRAIN ISCHEMIA; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DRUG WITHDRAWAL; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAUTERINE INFECTION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; VACCINATION;

CHRONIC DISEASE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISEASES; SCHIZOPHRENIA;

EID: 34447131488     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.7.789     Document Type: Review

References (101)

1. Muller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. The immune system and schizophrenia. An integrative view. Ann. NY Acad. Sci. 917, 456-467 (2000).
2. Maes M, Bocchio Chiavetto L, Bignotti S et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 54, 281-291 (2002).
3. Sirota P, Meiman M, Herschko R, Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-α and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res. 134, 151-159 (2005).
4. Rapaport MH, Lohr JB. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand. 90, 311-315 (1994).
5. Brown AS, Cohen P, Harkavy-Friedman J et al. A.E. Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol. Psychiatry 49, 473-486 (2001).
6. Mednick SA, Machon RA, Huttunen MO, Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry 45, 189-192 (1988).
7. Brown AS, Schaefer CA, Quesenberry CP Jr, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am. J. Psychiatry 162, 767-773 (2005).
8. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH. Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry 58, 1032-1037 (2001).
9. Brown AS, Schaefer CA, Quesenberry CP Jr, Shen L, Susser ES. No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia? Am. J. Psychiatry 163, 2178-2180 (2006).
10. Borrell J, Vela JM, Arevalo-Martin A, Molina-Holgado E, Guaza C. Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 26, 204-215 (2002).
11. Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol. Psychiatry 59, 546-554 (2006).
12. Eagles JM, Gibson I, Bremner MH, Clunie F, Ebmeier KP, Smith NC. Obstetric complications in DSM-III schizophrenics and their siblings. Lancet 335, 1139-1141 (1990).
13. Jones PB, Rantakallio P, Hartikainen AL, Isohanni M, Sipila P. Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal complications: a 28-year follow-up of the 1966 north Finland general population birth cohort. Am. J. Psychiatry 155, 355-364 (1998).
14. Parnas J, Schulsinger F, Teasdale TW, Schulsinger H, Feldman PM, Mednick SA. Perinatal complications and clinical outcome within the schizophrenia spectrum. Br. J. Psychiatry 140, 416-420 (1982).
15. Sacker A, Done DJ, Crow TJ, Golding J. Antecedents of schizophrenia and affective illness. Obstetric complications. Br. J. Psychiatry 166, 734-741 (1995).
16. Hultman CM, Ohman A, Cnattingius S, Wieselgren IM, Lindstrom LH. Prenatal and neonatal risk factors for schizophrenia. Br. J. Psychiatry 170, 128-133 (1997).
17. Zornberg GL, Buka SL, Tsuang MT. Hypoxic-ischemia-related fetal/neonatal complications and risk of schizophrenia and other nonaffective psychoses: a 19-year longitudinal study. Am. J. Psychiatry 157, 196-202 (2000).
18. Rosso IM, Cannon TD, Huttunen T, Huttunen MO, Lonnqvist J, Gasperoni TL. Obstetric risk factors for early-onset schizophrenia in a Finnish birth cohort. Am. J. Psychiatry 157, 801-807 (2000).
19. Done, DJ, Johnstone EC, Frith CD, Golding J, Shepherd PM, Crow TJ. Complications of pregnancy and delivery in relation to psychosis in adult life: data from the British perinatal mortality survey sample. Br. Med. J. 302, 1576-1580 (1991).
20. McCreadie RG, Hall DJ, Berry IJ, Robertson LJ, Ewing JI, Geals MF. The Nithsdale schizophrenia surveys. X: obstetric complications, family history and abnormal movements. Br. J. Psychiatry 160, 799-805 (1992).
21. Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH. Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biol. Psychiatry 50, 743-749 (2001). • Good discussion of possible underlying mechanisms relating cytokines to schizophrenia.
22. Hara H, Friedlander RM, Gagliardini V et al. Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl Acad. Sci. USA 94, 2007-2012 (1997).
23. Barone FC, Arvin B, White RF et al. Tumor necrosis factor-α. A mediator of focal ischemic brain injury. Stroke 28, 1233-1244 (1997).
24. Bruce AJ, Boling W, Kindy MS et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 2, 788-794 (1996).
25. Hopkins SJ, Rothwell NJ. Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci. 18, 83-88 (1995).
26. Vitkovic L, Bockaert J, Jacque C. "Inflammatory" cytokines: neuromodulators in normal brain? J. Neurochem. 74, 457-471 (2000).
27. Mehler MF, Kessler JA. Hematolymphopoietic and inflammatory cytokines in neural development. Trends Neurosci. 20, 357-365 (1997).
28. Gilmore JH, Jarskog LF. Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophr. Res. 24, 365-367 (1997).
29. Brown AS, Hooton J, Schaefer CA et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry 161, 889-895 (2004).
30. Sastry PS, Rao KS. Apoptosis and the nervous system. J. Neurochem. 74, 1-20 (2000).
31. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462 (1995).
32. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res. 81, 47-63 (2006).
33. Benes FM, Walsh J, Bhattacharyya S, Sheth A, Berretta S. DNA fragmentation decreased in schizophrenia but not bipolar disorder. Arch. Gen. Psychiatry 60, 359-364 (2003).
34. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr. Bull. 32, 200-202 (2006). •• Concise review of maternal exposure to different infectious agents and the risk of schizophrenia.
35. Goff DC. Pharmacologic implications of neurobiological models of schizophrenia. Harv. Rev. Psychiatry 13, 352-359 (2005).
36. Gilmore JH, Jarskog LF, Vadlamudi S. Maternal infection regulates BDNF and NGF expression in fetal and neonatal brain and maternal-fetal unit of the rat. J. Neuroimmunol. 138, 49-55 (2003).
37. Maes M, Bocchio Chiavetto L, Bignotti S et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur. Neuropsychopharmacol. 10, 119-124 (2000).
38. Lin, A, Kenis G, Bignotti S et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 32, 9-15 (1998).
39. Zhang, XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 65, 940-947 (2004).
40. Larsen GL, Henson PM. Mediators of inflammation. Annu. Rev. Immunol. 1, 335-359 (1983).
41. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-? in schizophrenia? Schizophr. Res. 26, 227-233 (1997).
42. Schattner A, Cori Y, Hahn T, Sirota P. No evidence for autoimmunity in schizophrenia. J. Autoimmun. 9, 661-666 (1996).
43. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry 150, 1408-1410 (1993).
44. el-Mallakh RS, Suddath RL, Wyatt RJ. Interleukin-1α and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog. Neuropsychopharmacol. Biol. Psychiatry 17, 383-391 (1993).
45. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr. Res. 25, 123-129 (1997).
46. McAllister CG, van Kammen DP, Rehn TJ et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry 152, 1291-1297 (1995).
47. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin. Chem. 46, 461-468 (2000).
48. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 164, 1010-1014 (2004).
49. Lesperance F, Frasure-Smith N, Theroux P, Irwin M. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am. J. Psychiatry. 161, 271-277 (2004).
50. Yaffe K, Lindquist K, Penninx BW et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61, 76-80 (2003). •• Major study relating inflammation to cognitive impairment.
51. Weuve J, Ridker PM, Cook NR, Buring JE, Grodstein F. High-sensitivity C-reactive protein and cognitive function in older women. Epidemiology 17, 183-189 (2006).
52. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 149, 267-271 (2007).
53. Dziedzic T. Systemic inflammatory markers and risk of dementia. Am. J. Alzheimers Dis. Other Demen. 21, 258-262 (2006).
54. Grunze HC, Rainnie DG, Hasselmo ME et al. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 16, 2034-2043 (1996).
55. Green MF, Nuechterlein KH, Gold JM et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56, 301-307 (2004).
56. Bachneff SA. Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Schizophr. Bull. 22, 163-182 (1996).
57. Shinba T, Nagano M, Kariya N et al. Near-infrared spectroscopy analysis of frontal lobe dysfunction in schizophrenia. Biol. Psychiatry 55, 154-164 (2004).
58. Lahti AC, Holcomb HH, Medoff DR, Weiler MA, Tamminga CA, Carpenter WT Jr. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am. J. Psychiatry 158, 1797-1808 (2001).
59. Vaiva G, Cottencin O, Llorca PM et al. Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 481-485 (2002).
60. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med. Genet. 6, 7 (2005).
61. Biessels GJ, Kamal A, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res. 800, 125-135 (1998).
62. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis. Assoc. Disord. 20, 298-301 (2006).
63. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 74, 270-280 (2001).
64. Park CR, Seeley RJ, Craft S, Woods SC. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav. 68, 509-514 (2000).
65. Steen E, Terry BM, Rivera EJ et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this Type 3 diabetes? J. Alzheimers Dis. 7, 63-80 (2005).
66. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801 (2006).
67. Hotamisligil GS. Inflammation and metabolic disorders. Nature 444, 860-867 (2006). •• In-depth review relating inflammation to metabolic disorders.
68. Henderson DC, Cagliero E, Copeland PM et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry 62, 19-28 (2005).
69. Newcomer JW, Haupt DW, Fucetola R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 59, 337-345 (2002).
70. Muller N, Riedel M, Scheppach C et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 159, 1029-1034 (2002).
71. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry 57, 1594-1596 (2005).
72. McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80, 19-32 (2005).
73. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433-438 (2004).
74. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288, 2709-2716 (2002).
75. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 160, 284-289 (2003).
76. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br. J. Psychiatry 47, S76-S79 (2004).
77. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry 65, 267-272 (2004).
78. Henderson DC, Nguyen DD, Copeland PM et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J. Clin. Psychiatry 66, 1116-1121 (2005).
79. Bonora E, Kiechl S, Willeit J et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47, 1643-1649 (1998).
80. Kitabchi AE, Temprosa M, Knowler WC et al. Role of insulin secretion and sensitivity in the evolution of Type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54, 2404-2414 (2005).
81. Lillioja S, Mott DM, Spraul M et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N. Engl. J. Med. 329, 1988-1992 (1993).
82. Semenkovich CF. Insulin resistance and atherosclerosis. J. Clin. Invest. 116, 1813-1822 (2006).
83. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of Type 2 diabetes development. Diabetes Care 24, 89-94 (2001).
84. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111-1119 (2005).
85. Sjoholm A, Nystrom T. Inflammation and the etiology of Type 2 diabetes. Diabetes Metab. Res. Rev. 22, 4-10 (2006).
86. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993).
87. Dandona P, Aljada A, Chaudhuri A, Mohanty P. Endothelial dysfunction, inflammation and diabetes. Rev. Endocr. Metab. Disord. 5, 189-197 (2004).
88. White MF. The insulin signalling system and the IRS proteins. Diabetologia 40, S2-S17 (1997).
89. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271, 665-668 (1996).
90. Diamant M, Heine RJ. Thiazolidinediones in Type 2 diabetes mellitus: current clinical evidence. Drugs 63, 1373-1405 (2003).
91. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 106, 679-684 (2002).
92. Esposito K, Ciotola M, Carleo D et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29, 1071-1076 (2006).
93. Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M. Association between -G308A tumor necrosis factor-α gene polymorphism and schizophrenia. Mol. Psychiatry 6, 79-82 (2001).
94. Schwab SG, Mondabon S, Knapp M et al. Association of tumor necrosis factor-α gene-G308A polymorphism with schizophrenia. Schizophr. Res. 65, 19-25 (2003).
95. Tan EC, Chong SA, Tan CH, Teo YY, Peng K, Mahendran R. Tumor necrosis factor-α gene promoter polymorphisms in chronic schizophrenia. Biol. Psychiatry 54, 1205-1211 (2003).
96. Riedel M, Kronig H, Schwarz MJ et al. No association between the G308A polymorphism of the tumor necrosis factor-α gene and schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 252, 232-234 (2002).
97. Tsai SJ, Hong CJ, Yu YW, Lin CH, Liu LL. No association of tumor necrosis factor-α gene polymorphisms with schizophrenia or response to clozapine. Schizophr. Res. 65, 27-32 (2003).
98. Katila H, Hanninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol. Psychiatry 4, 179-181 (1999).
99. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40, 171-176 (1999).
100. Owen BM, Eccleston D, Ferrier IN, Young AH. Raised levels of plasma interleukin-1β in major and postviral depression. Acta Psychiatr. Scand. 103, 226-228 (2001).
101. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370-379 (2000).